PKU Healthcare
PKU Healthcare is a Chinese pharmaceutical company with roots in Chongqing's Southwest Synthetic Pharmaceutical enterprise and ownership links to PKU Founder Group and Peking University.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
PKU Healthcare is a Chinese pharmaceutical company formerly known as PKU International Healthcare Group Southwest Pharmaceutical Co., Ltd. and, before that, Southwest Synthetic Pharmaceuticals. Its corporate history is rooted in Southwest Synthetic Pharmaceutical Factory, a Chongqing pharmaceutical enterprise founded in 1965. The listed company itself was incorporated on 18 May 1993 as Southwest Synthetic Pharmaceutical Co., Ltd., a subsidiary of the factory, which was owned by the Chongqing Municipal People's Government. The company experienced significant ownership and financial restructuring during the early 2000s. Financial difficulties at the original operating group led to changes in shareholding, debt arrangements, and control. In 2003, management of the relevant intermediate holding structure was entrusted to PKU Founder Group. Later that year, Founder Group agreed with China Development Bank and Chongqing Chemical and Pharmaceutical Holding Group on a restructuring that gave Founder Group indirect majority control of the intermediate pharmaceutical group and, consequently, a substantial indirect interest in the listed company. From that point, the company became associated with the Peking University corporate system through PKU Founder Group and PKU Healthcare Group. In 2013, the company adopted the PKU Healthcare name, reflecting its integration into the broader PKU healthcare and pharmaceutical organization. The rebranding distinguished the company from its earlier Southwest Synthetic identity while preserving its connection with the Chongqing pharmaceutical business from which it originated. The company is therefore best understood as a corporate pharmaceutical entity rather than a consumer-facing product brand. PKU Healthcare's principal business identity is pharmaceutical manufacturing and related healthcare operations. The available reference material does not provide a complete, current catalogue of medicines, therapeutic areas, proprietary brands, facilities, or international subsidiaries, so those details cannot be reliably enumerated here. Its ownership history, however, is comparatively well documented. PKU Healthcare Group was the largest shareholder in the cited 2015 ownership structure, with direct and indirect holdings of approximately 40.38%. PKU Founder Group held control of PKU Healthcare Group, while Peking University-related entities held interests in Founder Group. On that basis, the company was described as a state-owned enterprise in a broad or indirect sense because Peking University is supervised by China's Ministry of Education, although the immediate corporate ownership chain included corporate and market-based entities. The company's ownership and capital structure also became connected with regulatory scrutiny. In 2013, shares were transferred to Beijing Zenith Holdings and to the Peking University Education Foundation. The cited account states that Zenith Holdings did not pay PKU Healthcare Group as agreed because of financial difficulties and that a related proxy-holding arrangement was subsequently made with PKU Resources Group Holdings. The China Securities Regulatory Commission fined the companies involved in 2016. The episode illustrates the complexity of PKU Healthcare's shareholder arrangements and the regulatory risks associated with related-party transactions and beneficial ownership disclosures. PKU Healthcare's present identity is consequently shaped by three factors: its origin as a Chongqing synthetic-pharmaceutical enterprise, its transformation through debt and ownership restructuring, and its incorporation into a healthcare group associated with Peking University. Publicly available material supplied for this entry does not establish a current executive roster, website, detailed product portfolio, or verified international footprint. Those fields remain limited to information that can be supported without speculation.
History
PKU Healthcare traces its origins to Southwest Synthetic Pharmaceutical Factory, established in Chongqing in 1965. The factory was owned by the Chongqing Municipal People's Government and later became the parent of the listed pharmaceutical company that developed into PKU Healthcare. On 18 May 1993, Southwest Synthetic Pharmaceutical Co., Ltd. was incorporated as a subsidiary of the factory. The company operated under the Southwest Synthetic Pharmaceuticals identity during its early listed-company history. Financial difficulties within the parent group subsequently produced a series of ownership and debt changes. In 2001, Sichuan No. 2 Electric Power Construction acquired a minority interest of 1.26% from the parent entity. In 2002, 47.31% of the listed company's shares were entrusted to the private company Southern Tongzheng Investment by the original parent. A major restructuring took place in 2003. China Huarong Asset Management made a public offer relating to the parent entity's debt, and the parent was reincorporated on 4 September as Chongqing Southwest Synthetic Pharmaceutical Co., Ltd. Part of the debt was converted into equity, resulting in China Development Bank holding 39.80% of the intermediate company. Earlier in the year, management of Southwest Synthetic Pharmaceutical Group had been entrusted to PKU Founder Group. On 29 September, Founder Group, China Development Bank, and Chongqing Chemical and Pharmaceutical Holding Group reached an agreement under which Founder Group subscribed for new capital of approximately CNY 300 million and obtained majority control of the intermediate group. China Development Bank exited its position through a transfer to the original major shareholder. Founder Group thereby became the indirect major shareholder of the listed company through a holding of approximately 47.31%. The company's relationship with Peking University developed through PKU Founder Group and PKU Healthcare Group. It became an indirect subsidiary of Peking University in 2003. The company received assets from its former parent group after the Founder Group restructuring. In 2013, it changed its corporate name to PKU Healthcare Corp., Ltd., known in English as PKU Healthcare, marking its alignment with the PKU healthcare organization. The shareholder structure continued to change during the 2010s. PKU Healthcare Group held 51.95% of the company at the end of 2012. In 2013, 6.71% was sold to Beijing Zenith Holdings and a further 5.03% to the Peking University Education Foundation. The cited account states that Zenith Holdings did not pay PKU Healthcare Group as expected and that the shares were instead subject to an arrangement under which PKU Resources Group Holdings acted as the beneficial or proxy-related holder. Zenith later disposed of additional portions of its interest in 2014 and 2015. PKU Healthcare Group also announced a share repurchase program in November 2014 for up to 2% of the company's shares. A purchase representing 0.18% was reported in July 2015, at which point the cited account gives a price of CNY 18.28 per share. The program was announced as completed in October 2015. As of 31 December 2015, PKU Healthcare Group held approximately 40.38% of PKU Healthcare directly and indirectly through Southwest Pharmaceutical Group, making it the largest shareholder. PKU Founder Group owned 85.60% of PKU Healthcare Group, with the remaining interest attributed to Peking University. Peking University Asset Management held 70% of PKU Founder Group and an additional indirect interest in PKU Healthcare. Because of these links to a university supervised by China's Ministry of Education, the company was described as state-owned in a broad definitional sense. The shareholder arrangements became the subject of regulatory action. The supplied reference states that the China Securities Regulatory Commission fined the companies involved in 2016. Beyond the ownership and regulatory history, the available material does not provide sufficient verified information about the company's current product brands, management, facilities, revenue, or present operating status. PKU Healthcare's documented historical significance therefore lies primarily in its transformation from a Chongqing municipal pharmaceutical enterprise into a Peking University-associated listed healthcare company.
- 2016
Regulatory fines related to share arrangements
[1]The China Securities Regulatory Commission fined companies involved in the share-transfer and proxy-holding arrangements described in the company's ownership history.
- 2015
Share repurchase program completed
[1]The company announced completion of the repurchase program after reporting a purchase representing 0.18% of the shares.
- 2014
Share repurchase program announced
[1]PKU Healthcare Group announced a plan to repurchase no more than 2% of PKU Healthcare's shares from the public market.
- 2013
Company renamed PKU Healthcare
[1]The company changed its name from PKU International Healthcare Group Southwest Pharmaceutical Co., Ltd. to PKU Healthcare Corp., Ltd.
- 2003
Founder Group becomes indirect controlling shareholder
[1]A debt and equity restructuring gave PKU Founder Group majority control of the intermediate pharmaceutical group and an indirect interest of approximately 47.31% in the listed company.
- 2001
Minority share transfer during financial difficulties
[1]Sichuan No. 2 Electric Power Construction acquired a 1.26% interest from the parent entity amid financial difficulties.
- 1993
Southwest Synthetic Pharmaceutical Co., Ltd. is incorporated
[1]The listed pharmaceutical company was incorporated on 18 May 1993 as a subsidiary of Southwest Synthetic Pharmaceutical Factory.
- 1965
Southwest Synthetic Pharmaceutical Factory is established
[1]The Chongqing-based Southwest Synthetic Pharmaceutical Factory, the predecessor of the later listed company, was founded under municipal ownership.
Products and positioning
A Chinese pharmaceutical and healthcare company positioned within the Peking University-associated healthcare corporate system, with historical roots in Chongqing's synthetic-pharmaceutical manufacturing sector.
Pharmaceuticals
Pharmaceutical products
PKU Healthcare is identified in the reference material as a pharmaceutical company, but the supplied sources do not establish a reliable current list of branded medicines, active ingredients, therapeutic categories, or product families. Its historical operating base was Southwest Synthetic Pharmaceutical, a Chongqing manufacturer associated with synthetic pharmaceutical production.
Controversies
2016
Regulatory action over shareholder arrangements
The supplied reference states that the China Securities Regulatory Commission fined PKU Healthcare Group, Beijing Zenith Holdings, and PKU Resources Group Holdings after the disclosed share-transfer and proxy-holding arrangements. The episode concerned ownership, payment, and control arrangements rather than a pharmaceutical product safety issue.
Brand decisions
2014
Share repurchase programOtherBackground
PKU Healthcare Group announced a market repurchase program during a period of continuing changes in the company's shareholder structure.
Action taken
The group announced an intention to buy back no more than 2% of PKU Healthcare's shares from the public market.
Aftermath
A purchase representing 0.18% of the shares was reported in July 2015, and the program was later announced as completed.
Reported repurchase price. CNY 18.28 per share for the July 2015 purchase (July 2015)
2013
Corporate rebranding as PKU HealthcareStrategyBackground
The company had become an indirect subsidiary within the Peking University-associated healthcare structure after the 2003 restructuring.
Action taken
The company changed its name from PKU International Healthcare Group Southwest Pharmaceutical Co., Ltd. to PKU Healthcare Corp., Ltd.
Aftermath
The new name emphasized its connection with the PKU healthcare organization while retaining its pharmaceutical-company identity.
2003
Restructuring under Founder Group managementStrategyBackground
Debt problems and changes in the ownership of Southwest Synthetic Pharmaceutical created a need for a broader financial and corporate restructuring.
Action taken
Founder Group took over management of the intermediate pharmaceutical group and subscribed for new capital, while China Development Bank exited its interest through an agreed transfer.
Aftermath
Founder Group became the indirect major shareholder, and the company became associated with the Peking University corporate system.
Founder Group capital subscription. CNY 300 million subscription for new share capital (2003)
Recent events
- 2013
PKU Healthcare adopts its current corporate name[1]
Other · Leadership change
The company formerly known as PKU International Healthcare Group Southwest Pharmaceutical Co., Ltd. changed its name to PKU Healthcare Corp., Ltd., aligning its identity with the PKU healthcare organization.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pku-healthcare · Editorial policy · How profiles are compiled